PBYI - Puma Biotechnology and CANbridge terminate NERLYNX license agreement

Puma Biotechnology (PBYI) and CANbridge Pharmaceuticals have agreed to terminate their 2018 license agreement, in which Puma granted CANbridge exclusive rights to develop and commercialize NERLYNX (neratinib) in Greater China, and to settle their arbitration related to the license agreement.Separately, Puma and  French pharmaceutical company Pierre Fabre have agreed to extend the terms of the 2019 license agreement which grants Pierre Fabre exclusive rights to develop and commercialize NERLYNX (neratinib) within Europe, Turkey, Middle East and Africa.Neratinib is approved in the US for both the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy and HER2-positive metastatic breast cancer and is marketed in the US as NERLYNX (neratinib) tablets.

For further details see:

Puma Biotechnology and CANbridge terminate NERLYNX license agreement